Current Report Filing (8-k)

Date : 11/12/2019 @ 12:27PM
Source : Edgar (US Regulatory)
Stock : Acorda Therapeutics Inc (ACOR)
Quote : 1.76  -0.08 (-4.35%) @ 11:50PM
After Hours
Last Trade
Last $ 1.78 ▲ 0.02 (1.13%)

Current Report Filing (8-k)

false ACORDA THERAPEUTICS INC 0001008848 0001008848 2019-11-12 2019-11-12

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2019

 

Acorda Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-31938

13-3831168

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

420 Saw Mill River Road,

Ardsley, NY

 

10502

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (914) 347-4300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock (Par Value $0.01)

 

ACOR

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 


 

Item 5.02 Departure of Directors or Certain Officers; Elections of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 12, 2019, Acorda Therapeutics, Inc. (the “Company”) announced that Jane Wasman, the Company’s President, International & General Counsel and one of its named executive officers, will resign from the Company effective as of January 1, 2020.

 

The Company has entered into a consulting agreement with Ms. Wasman, effective as of January 1, 2020, pursuant to which she will provide certain consulting services to the Company, as requested by the Company, from January 1, 2020 through December 31, 2020, in consideration for cash compensation at an hourly rate and the Company’s agreement to modify Ms. Wasman’s outstanding stock options to allow for their continued vesting during the consultancy period, and exercise (subject to the applicable option exercise date) for 12 months thereafter. Ms. Wasman will also receive certain compensation and benefits to which she is entitled pursuant to her existing employment agreement with the Company.

 

Andrew Mayer, Deputy General Counsel, will assume responsibility for legal operations following the effective date of Ms. Wasman’s resignation.

 

A copy of the press release announcing Ms. Wasman’s resignation is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.

 

Item 9.01Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.

 

Description

 

99.1

Press Release dated November 12, 2019

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Acorda Therapeutics, Inc.

 

 

 

November 12, 2019

By:

/s/ David Lawrence

 

 

Name: David Lawrence

 

 

Title: Chief, Business Operations and Principal Accounting Officer

 

 

Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Acorda Therapeutics Charts.

Acorda Therapeutics (NASDAQ:ACOR)
Intraday Stock Chart

Today : Saturday 14 December 2019

Click Here for more Acorda Therapeutics Charts.

Latest ACOR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.